{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T22:26:54Z","timestamp":1793917614815,"version":"4.8.0"},"reference-count":99,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2022,8,18]],"date-time":"2022-08-18T00:00:00Z","timestamp":1660780800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2022,8,18]],"date-time":"2022-08-18T00:00:00Z","timestamp":1660780800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Osteoporos Int"],"published-print":{"date-parts":[[2023,2]]},"DOI":"10.1007\/s00198-022-06523-7","type":"journal-article","created":{"date-parts":[[2022,8,18]],"date-time":"2022-08-18T12:03:17Z","timestamp":1660824197000},"page":"213-238","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":150,"title":["Role of Wnt signaling and sclerostin in bone and as therapeutic targets in skeletal disorders"],"prefix":"10.1007","volume":"34","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3678-4922","authenticated-orcid":false,"given":"Francesca","family":"Marini","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8576-9606","authenticated-orcid":false,"given":"Francesca","family":"Giusti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8376-7404","authenticated-orcid":false,"given":"Gaia","family":"Palmini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8741-0592","authenticated-orcid":false,"given":"Maria Luisa","family":"Brandi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,8,18]]},"reference":[{"issue":"1","key":"6523_CR1","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3109\/08977","volume":"31","author":"K Saito-Diaz","year":"2013","unstructured":"Saito-Diaz K, Chen TW, Wang X, Thorne CA, Wallace HA, Page-McCaw A, Lee E (2013) The way Wnt works: components and mechanism. Growth Factors 31(1):1\u201331. https:\/\/doi.org\/10.3109\/08977","journal-title":"Growth Factors"},{"issue":"19","key":"6523_CR2","doi-asserted-by":"publisher","first-page":"17570","DOI":"10.18632\/oncotarget.4100.194.2012.752737","volume":"6","author":"C Chen","year":"2015","unstructured":"Chen C, Zhao M, Tian A, Zhang X, Yao Z, Ma X (2015) Aberrant activation of Wntbeta-catenin signaling drives proliferation of bone sarcoma cells. Oncotarget 6(19):17570\u201383. https:\/\/doi.org\/10.18632\/oncotarget.4100.194.2012.752737","journal-title":"Oncotarget"},{"issue":"22","key":"6523_CR3","doi-asserted-by":"publisher","first-page":"5525","DOI":"10.3390\/ijms20225525","volume":"20","author":"K Maeda","year":"2019","unstructured":"Maeda K, Kobayashi Y, Koide M, Uehara S, Okamoto M, Ishihara A, Kayama T, Saito M, Marumo K (2019) The regulation of bone metabolism and disorders by Wnt signaling. Int J Mol Sci 20(22):5525. https:\/\/doi.org\/10.3390\/ijms20225525","journal-title":"Int J Mol Sci"},{"key":"6523_CR4","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.biocel.2016.05.015","volume":"77(PtA)","author":"P Duan","year":"2016","unstructured":"Duan P, Bonewald LF (2016) The role of the wnt\/beta-catenin signaling pathway in formation and maintenance of bone and teeth. Int J Biochem Cell Biol 77(PtA):23\u201329. https:\/\/doi.org\/10.1016\/j.biocel.2016.05.015","journal-title":"Int J Biochem Cell Biol"},{"issue":"3","key":"6523_CR5","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1016\/j.molcel.2015.03.015","volume":"58","author":"X Jiang","year":"2015","unstructured":"Jiang X, Charlat O, Zamponi R, Yang Y, Cong F (2015) Dishevelled promotes Wnt receptor degradation through recruitment of ZNRF3\/RNF43 E3 ubiquitin ligases. Mol Cell 58(3):522\u2013533. https:\/\/doi.org\/10.1016\/j.molcel.2015.03.015","journal-title":"Mol Cell"},{"issue":"2","key":"6523_CR6","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1210\/edrv.21.2.0395","volume":"21","author":"SC Manolagas","year":"2000","unstructured":"Manolagas SC (2000) Birth and death of bone cells: basic regulatory mechanisms and implications for the pathogenesis and treatment of osteoporosis. Endocr Rev 21(2):115\u2013137. https:\/\/doi.org\/10.1210\/edrv.21.2.0395","journal-title":"Endocr Rev"},{"issue":"1","key":"6523_CR7","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1016\/j.bone.2012.12.052","volume":"55","author":"Y Wan","year":"2013","unstructured":"Wan Y, Lu C, Cao J, Zhou R, Yao Y, Yu J, Zhang L, Zhao H, Li H, Zhao J, Zhu X, He L, Liu Y, Yao Z, Yang X, Guo X (2013) Osteoblastic Wnts differentially regulate bone remodeling and the maintenance of bone marrow mesenchymal stem cells. Bone 55(1):258\u2013267. https:\/\/doi.org\/10.1016\/j.bone.2012.12.052","journal-title":"Bone"},{"issue":"2","key":"6523_CR8","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1016\/j.bone.2012.12.016","volume":"53","author":"C Lu","year":"2013","unstructured":"Lu C, Wan Y, Cao J, Zhu X, Yu J, Zhou R, Yao Y, Zhang L, Zhao H, Li H, Zhao J, He L, Ma G, Yang X, Yao Z, Guo X (2013) Wnt-mediated reciprocal regulation between cartilage and bone development during endochondral ossification. Bone 53(2):566\u2013574. https:\/\/doi.org\/10.1016\/j.bone.2012.12.016","journal-title":"Bone"},{"issue":"6","key":"6523_CR9","doi-asserted-by":"publisher","first-page":"630","DOI":"10.1111\/joim.12368","volume":"277","author":"UH Lerner","year":"2015","unstructured":"Lerner UH, Ohlsson C (2015) The WNT system: background and its role in bone. J Intern Med 277(6):630\u2013649. https:\/\/doi.org\/10.1111\/joim.12368","journal-title":"J Intern Med"},{"issue":"7","key":"6523_CR10","doi-asserted-by":"publisher","first-page":"2678","DOI":"10.1172\/JCI92617","volume":"127","author":"KS Joeng","year":"2017","unstructured":"Joeng KS, Lee YC, Lim J, Chen Y, Jiang MM, Munivez E, Ambrose C, Lee BH (2017) Osteocyte-specific WNT1 regulates osteoblast function during bone homeostasis. J Clin Invest 127(7):2678\u20132688. https:\/\/doi.org\/10.1172\/JCI92617","journal-title":"J Clin Invest"},{"key":"6523_CR11","doi-asserted-by":"publisher","first-page":"949","DOI":"10.1002\/jbmr.2757","volume":"31","author":"F Grassi","year":"2016","unstructured":"Grassi F, Tyagi AM, Calvert JW, Gambari L, Walker LD, Yu M, Robinson J, Li J-Y, Lisignoli G, Vaccaro C, Adams J, Pacifici R (2016) Hydrogen sulfide is a novel regulator of bone formation implicated in the bone loss induced by estrogen deficiency. J Bone Miner Res 31:949\u2013963. https:\/\/doi.org\/10.1002\/jbmr.2757","journal-title":"J Bone Miner Res"},{"issue":"6","key":"6523_CR12","doi-asserted-by":"publisher","first-page":"1210","DOI":"10.1002\/jcb.20284","volume":"93","author":"GM Boland","year":"2004","unstructured":"Boland GM, Perkins G, Hall DJ, Tuan RS (2004) Wnt 3a promotes proliferation and suppresses osteogenic differentiation of adult human mesenchymal stem cells. J Cell Biochem 93(6):1210\u20131230. https:\/\/doi.org\/10.1002\/jcb.20284","journal-title":"J Cell Biochem"},{"issue":"1\u20132","key":"6523_CR13","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1089\/ten.TEA.2016.0387","volume":"24","author":"J Shen","year":"2018","unstructured":"Shen J, Chen X, Jia H, Meyers CA, Shrestha S, Asatrian G, Ding C, Tsuei R, Zhang X, Peault B, Ting K, Soo C, James AW (2018) Effects of WNT3A and WNT16 on the osteogenic and adipogenic differentiation of perivascular stem\/stromal cells. Tissue Eng Part A 24(1\u20132):68\u201380. https:\/\/doi.org\/10.1089\/ten.TEA.2016.0387","journal-title":"Tissue Eng Part A"},{"issue":"11","key":"6523_CR14","doi-asserted-by":"publisher","first-page":"2358","DOI":"10.1016\/j.cellsig.2014.07.018","volume":"26","author":"K Hamamura","year":"2014","unstructured":"Hamamura K, Chen A, Nishimura A, Tanjung N, Sudo A, Yokota H (2014) Predicting and validating the pathway of Wnt3a-driven suppression of osteoclastogenesis. Cell Signal 26(11):2358\u20132369. https:\/\/doi.org\/10.1016\/j.cellsig.2014.07.018","journal-title":"Cell Signal"},{"issue":"1","key":"6523_CR15","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1016\/j.devcel.2006.11.003","volume":"12","author":"X Tu","year":"2007","unstructured":"Tu X, Joeng KS, Nakayama KI, Nakayama K, Rajagopal J, Carroll TJ, McMahon AP, Long F (2007) Noncanonical Wnt signaling through G protein-linked PKCdelta activation promotes bone formation. Dev Cell 12(1):113\u2013127. https:\/\/doi.org\/10.1016\/j.devcel.2006.11.003","journal-title":"Dev Cell"},{"issue":"1","key":"6523_CR16","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1016\/j.bbrc.2011.08.061","volume":"413","author":"W Qiu","year":"2011","unstructured":"Qiu W, Chen L, Kassem M (2011) Activation of non-canonical Wnt\/JNK pathway by Wnt3a is associated with differentiation fate determination of human bone marrow stromal (mesenchymal) stem cells. Biochem Biophys Res Commun 413(1):98\u2013104. https:\/\/doi.org\/10.1016\/j.bbrc.2011.08.061","journal-title":"Biochem Biophys Res Commun"},{"issue":"42","key":"6523_CR17","doi-asserted-by":"publisher","first-page":"30938","DOI":"10.1074\/jbc.M702391200","volume":"282","author":"J Chang","year":"2007","unstructured":"Chang J, Sonoyama W, Wang Z, Jin Q, Zhang C, Krebsbach PH, Giannobile W, Shi S, Wang CY (2007) Noncanonical Wnt-4 signaling enhances bone regeneration of mesenchymal stem cells in craniofacial defects through activation of p38 MAPK. J Biol Chem 282(42):30938\u201330948. https:\/\/doi.org\/10.1074\/jbc.M702391200","journal-title":"J Biol Chem"},{"issue":"9","key":"6523_CR18","doi-asserted-by":"publisher","first-page":"1009","DOI":"10.1038\/nm.3586","volume":"20","author":"B Yu","year":"2014","unstructured":"Yu B, Chang J, Liu Y, Li J, Kevork K, Al-Hezaimi K, Graves DT, Park NH, Wang CY (2014) Wnt4 signaling prevents skeletal aging and inflammation by inhibiting nuclear factor-kappaB. Nat Med 20(9):1009\u20131017. https:\/\/doi.org\/10.1038\/nm.3586","journal-title":"Nat Med"},{"issue":"3","key":"6523_CR19","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1038\/nm.2653","volume":"18","author":"K Maeda","year":"2012","unstructured":"Maeda K, Kobayashi Y, Udagawa N, Uehara S, Ishihara A, Mizoguchi T, Kikuchi Y, Takada I, Kato S, Kani S, Nishita M, Marumo K, Martin TJ, Minami Y, Takahashi N (2012) Wnt5a-Ror2 signaling between osteoblast-lineage cells and osteoclast precursors enhances osteoclastogenesis. Nat Med 18(3):405\u2013412. https:\/\/doi.org\/10.1038\/nm.2653","journal-title":"Nat Med"},{"issue":"9","key":"6523_CR20","doi-asserted-by":"publisher","first-page":"6170","DOI":"10.1074\/jbc.M109.054338","volume":"285","author":"R Bilkovski","year":"2010","unstructured":"Bilkovski R, Schulte DM, Oberhauser F, Gomolka M, Udelhoven M, Hettich MM, Roth B, Heidenreich A, Gutschow C, Krone W, Laudes M (2010) Role of WNT-5a in the determination of human mesenchymal stem cells into preadipocytes. J Biol Chem 285(9):6170\u20136178. https:\/\/doi.org\/10.1074\/jbc.M109.054338","journal-title":"J Biol Chem"},{"issue":"4","key":"6523_CR21","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1016\/j.bbrc.2012.05.039","volume":"422","author":"E Nemoto","year":"2012","unstructured":"Nemoto E, Ebe Y, Kanaya S, Tsuchiya M, Nakamura T, Tamura M, Shimauchi H (2012) Wnt5a signaling is a substantial constituent in bone morphogenetic protein-2-mediated osteoblastogenesis. Biochem Biophys Res Commun 422(4):627\u2013632. https:\/\/doi.org\/10.1016\/j.bbrc.2012.05.039","journal-title":"Biochem Biophys Res Commun"},{"issue":"8","key":"6523_CR22","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1038\/nrrheum.2009.137","volume":"5","author":"I Takada","year":"2009","unstructured":"Takada I, Kouzmenko AP, Kato S (2009) Wnt and PPARgamma signaling in osteoblastogenesis and adipogenesis. Nat Rev Rheumatol 5(8):442\u2013447. https:\/\/doi.org\/10.1038\/nrrheum.2009.137","journal-title":"Nat Rev Rheumatol"},{"key":"6523_CR23","doi-asserted-by":"publisher","first-page":"1003","DOI":"10.1242\/dev.00324","volume":"130","author":"Y Yang","year":"2003","unstructured":"Yang Y, Topol L, Lee H, Wu J (2003) Wnt5a and Wnt5b exhibit distinct activities in coordinating chondrocyte proliferation and differentiation. Development 130:1003\u20131015. https:\/\/doi.org\/10.1242\/dev.00324","journal-title":"Development"},{"issue":"2","key":"6523_CR24","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1016\/j.ydbio.2016.11.016","volume":"421","author":"IT Ling","year":"2017","unstructured":"Ling IT, Rochard L, Liao EC (2017) Distinct requirements of wls, wnt9a, wnt5b and gpc4 in regulating chondrocyte maturation and timing of endochondral ossification. Dev Biol 421(2):219\u2013232. https:\/\/doi.org\/10.1016\/j.ydbio.2016.11.016","journal-title":"Dev Biol"},{"issue":"2","key":"6523_CR25","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1016\/j.bone.2011.08.010","volume":"50","author":"WP Cawthorn","year":"2012","unstructured":"Cawthorn WP, Bree AJ, Yao Y, Du B, Hemati N, Martinez-Santiba\u00f1ez G, MacDougald OA (2012) Wnt6, Wnt10a and Wnt10b inhibit adipogenesis and stimulate osteoblastogenesis through a beta-catenin-dependent mechanism. Bone 50(2):477\u2013489. https:\/\/doi.org\/10.1016\/j.bone.2011.08.010","journal-title":"Bone"},{"issue":"6","key":"6523_CR26","doi-asserted-by":"publisher","first-page":"94","DOI":"10.3892\/ijmm.2021.4927","volume":"47","author":"L Yang","year":"2021","unstructured":"Yang L, Li Q, Zhang J, Li P, An P, Wang C, Hu P, Zou X, Dou X, Zhu L (2021) Wnt7a promotes the osteogenic differentiation of human mesenchymal stem cells. Int J Mol Med 47(6):94. https:\/\/doi.org\/10.3892\/ijmm.2021.4927","journal-title":"Int J Mol Med"},{"issue":"1","key":"6523_CR27","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pgen.1004145","volume":"10","author":"J Chen","year":"2014","unstructured":"Chen J, Tu X, Esen E, Joeng KS, Lin C, Arbeit JM, R\u00fcegg MA, Hall MN, Ma L, Long F (2014) WNT7B promotes bone formation in part through mTORC1. PLoS Genet 10(1):e1004145. https:\/\/doi.org\/10.1371\/journal.pgen.1004145","journal-title":"PLoS Genet"},{"issue":"9","key":"6523_CR28","doi-asserted-by":"publisher","first-page":"3324","DOI":"10.1073\/pnas.0408742102","volume":"102","author":"CN Bennett","year":"2005","unstructured":"Bennett CN, Longo KA, Wright WS, Suva LJ, Lane TF, Hankenson KD, MacDougald OA (2005) Regulation of osteoblastogenesis and bone mass by Wnt10b. Proc Natl Acad Sci U S A 102(9):3324\u20133329. https:\/\/doi.org\/10.1073\/pnas.0408742102","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"12","key":"6523_CR29","doi-asserted-by":"publisher","first-page":"1924","DOI":"10.1359\/jbmr.070810","volume":"22","author":"CN Bennett","year":"2007","unstructured":"Bennett CN, Ouyang H, Ma YL, Zeng Q, Gerin I, Sousa KM, Lane TF, Krishnan V, Hankenson KD, MacDougald OA (2007) Wnt10b increases postnatal bone formation by enhancing osteoblast differentiation. J Bone Miner Res 22(12):1924\u20131932. https:\/\/doi.org\/10.1359\/jbmr.070810","journal-title":"J Bone Miner Res"},{"issue":"33","key":"6523_CR30","doi-asserted-by":"publisher","first-page":"E2197","DOI":"10.1073\/pnas.1120407109","volume":"109","author":"Z Zhong","year":"2012","unstructured":"Zhong Z, Zylstra-Diegel CR, Schumacher CA, Baker JJ, Carpenter AC, Rao S, Yao W, Guan M, Helms JA, Lane NE, Lang RA, Williams BO (2012) Wntless functions in mature osteoblasts to regulate bone mass. Proc Natl Acad Sci U S A 109(33):E2197-204. https:\/\/doi.org\/10.1073\/pnas.1120407109","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"5","key":"6523_CR31","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1016\/j.devcel.2005.02.017","volume":"8","author":"DA Glass 2nd","year":"2005","unstructured":"Glass DA 2nd, Bialek P, Ahn JD, Starbuck M, Patel MS, Clevers H, Taketo MM, Long F, McMahon AP, Lang RA, Karsenty G (2005) Canonical Wnt signaling in differentiated osteoblasts controls osteoclast differentiation. Dev Cell 8(5):751\u2013764. https:\/\/doi.org\/10.1016\/j.devcel.2005.02.017","journal-title":"Dev Cell"},{"issue":"23","key":"6523_CR32","doi-asserted-by":"publisher","first-page":"4706","DOI":"10.1128\/MCB.05980-11","volume":"31","author":"W Wei","year":"2011","unstructured":"Wei W, Zeve D, Suh JM, Wang X, Du Y, Zerwekh JE, Dechow PC, Graff JM, Wan Y (2011) Biphasic and dosage-dependent regulation of osteoclastogenesis by beta-catenin. Mol Cell Biol 31(23):4706\u20134719. https:\/\/doi.org\/10.1128\/MCB.05980-11","journal-title":"Mol Cell Biol"},{"issue":"1","key":"6523_CR33","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1016\/j.bone.2012.09.029","volume":"52","author":"R Zhang","year":"2013","unstructured":"Zhang R, Oyajobi BO, Harris SE, Chen D, Tsao C, Deng HW, Zhao M (2013) Wnt\/beta-catenin signaling activates bone morphogenetic protein 2 expression in osteoblasts. Bone 52(1):145\u2013156. https:\/\/doi.org\/10.1016\/j.bone.2012.09.029","journal-title":"Bone"},{"issue":"4","key":"6523_CR34","doi-asserted-by":"publisher","first-page":"896","DOI":"10.1002\/jcb.22319","volume":"108","author":"M Zhang","year":"2009","unstructured":"Zhang M, Yan Y, Lim YB, Tang D, Xie R, Chen A, Tai P, Harris SE, Xing L, Qin YX, Chen D (2009) BMP-2 modulates beta-catenin signaling through stimulation of Lrp5 expression and inhibition of beta-TrCP expression in osteoblasts. J Cell Biochem 108(4):896\u2013905. https:\/\/doi.org\/10.1002\/jcb.22319","journal-title":"J Cell Biochem"},{"issue":"8B","key":"6523_CR35","doi-asserted-by":"publisher","first-page":"2448","DOI":"10.1111\/j.1582-4934.2008.00569.x","volume":"13","author":"N Tang","year":"2009","unstructured":"Tang N, Song WX, Luo J, Luo X, Chen J, Sharff KA, Bi Y, He BC, Huang JY, Zhu GH, Su YX, Jiang W, Tang M, He Y, Wang Y, Chen L, Zuo GW, Shen J, Pan X, Reid RR, Luu HH, Haydon RC, He TC (2009) BMP-9-induced osteogenic differentiation of mesenchymal progenitors requires functional canonical Wnt\/beta-catenin signalling. J Cell Mol Med 13(8B):2448\u20132464. https:\/\/doi.org\/10.1111\/j.1582-4934.2008.00569.x","journal-title":"J Cell Mol Med"},{"issue":"12","key":"6523_CR36","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0082436","volume":"8","author":"Y Gao","year":"2013","unstructured":"Gao Y, Huang E, Zhang H, Wang J, Wu N, Chen X, Wang N, Wen S, Nan G, Deng F, Liao Z, Wu D, Zhang B, Zhang J, Haydon RC, Luu HH, Shi LL, He TC (2013) Crosstalk between Wnt\/beta-catenin and estrogen receptor signaling synergistically promotes osteogenic differentiation of mesenchymal progenitor cells. PLoS ONE 8(12):e82436. https:\/\/doi.org\/10.1371\/journal.pone.0082436","journal-title":"PLoS ONE"},{"issue":"8","key":"6523_CR37","doi-asserted-by":"publisher","first-page":"3890","DOI":"10.1210\/en.2008-0140","volume":"149","author":"S Zanotti","year":"2008","unstructured":"Zanotti S, Smerdel-Ramoya A, Stadmeyer L, Durant D, Radtke F, Canalis E (2008) Notch inhibits osteoblast differentiation and causes osteopenia. Endocrinology 149(8):3890\u20133899. https:\/\/doi.org\/10.1210\/en.2008-0140","journal-title":"Endocrinology"},{"issue":"16","key":"6523_CR38","doi-asserted-by":"publisher","first-page":"3231","DOI":"10.1242\/dev.02480","volume":"133","author":"SJ Rodda","year":"2006","unstructured":"Rodda SJ, McMahon AP (2006) Distinct roles for Hedgehog and canonical Wnt signaling in specification, differentiation and maintenance of osteoblast progenitors. Development 133(16):3231\u20133244. https:\/\/doi.org\/10.1242\/dev.02480","journal-title":"Development"},{"issue":"2","key":"6523_CR39","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1038\/nm1538","volume":"13","author":"D Diarra","year":"2007","unstructured":"Diarra D, Stolina M, Polzer K, Zwerina J, Ominsky MS, Dwyer D, Korb A, Smolen J, Hoffmann M, Scheinecker C, van der Heide D, Landewe R, Lacey D, Richards WG, Schett G (2007) Dickkopf-1 is a master regulator of joint remodeling. Nat Med 13(2):156\u2013163. https:\/\/doi.org\/10.1038\/nm1538","journal-title":"Nat Med"},{"issue":"2","key":"6523_CR40","doi-asserted-by":"publisher","first-page":"1017","DOI":"10.3892\/mmr.2020.11152","volume":"22","author":"S Li","year":"2020","unstructured":"Li S, Yin Y, Yao L, Lin Z, Sun S, Zhang J, Li X (2020) TNF-alpha treatment increases DKK1 protein levels in primary osteoblasts via upregulation of DKK1 mRNA levels and downregulation of miR-335-5p. Mol Med Rep 22(2):1017\u20131025. https:\/\/doi.org\/10.3892\/mmr.2020.11152","journal-title":"Mol Med Rep"},{"issue":"6","key":"6523_CR41","doi-asserted-by":"publisher","first-page":"1030","DOI":"10.1016\/j.neuron.2011.07.021","volume":"71","author":"EY Rosen","year":"2011","unstructured":"Rosen EY, Wexler EM, Versano R, Coppola G, Gao F, Winden KD, Oldham MC, Martens LH, Zhou P, Farese RV Jr, Geschwind DH (2011) Functional genomic analyses identify pathways dysregulated by progranulin deficiency, implicating Wnt signaling. Neuron 71(6):1030\u20131042. https:\/\/doi.org\/10.1016\/j.neuron.2011.07.021","journal-title":"Neuron"},{"issue":"2","key":"6523_CR42","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1016\/j.bbrc.2010.08.031","volume":"402","author":"T Wang","year":"2010","unstructured":"Wang T, Xu Z (2010) miR-27 promotes osteoblast differentiation by modulating Wnt signaling. Biochem Biophys Res Commun 402(2):186\u2013189. https:\/\/doi.org\/10.1016\/j.bbrc.2010.08.031","journal-title":"Biochem Biophys Res Commun"},{"issue":"8","key":"6523_CR43","doi-asserted-by":"publisher","first-page":"1953","DOI":"10.1002\/jbmr.377","volume":"26","author":"J Zhang","year":"2011","unstructured":"Zhang J, Tu Q, Bonewald LF, He X, Stein G, Lian J, Chen J (2011) Effects of miR-335-5p in modulating osteogenic differentiation by specifically downregulating Wnt antagonist DKK1. J Bone Miner Res 26(8):1953\u20131963. https:\/\/doi.org\/10.1002\/jbmr.377","journal-title":"J Bone Miner Res"},{"issue":"12","key":"6523_CR44","doi-asserted-by":"publisher","first-page":"2466","DOI":"10.1002\/jbmr.3230","volume":"32","author":"L Zhang","year":"2017","unstructured":"Zhang L, Tang Y, Zhu X, Tu T, Sui L, Han Q, Yu L, Meng S, Zheng L, Valverde P, Tang J, Murray D, Zhou X, Drissi H, Dard MM, Tu Q, Chen J (2017) Overexpression of MiR-335-5p promotes bone formation and regeneration in mice. J Bone Miner Res 32(12):2466\u20132475. https:\/\/doi.org\/10.1002\/jbmr.3230","journal-title":"J Bone Miner Res"},{"key":"6523_CR45","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/j.bone.2013.09.015","volume":"58","author":"WB Zhang","year":"2014","unstructured":"Zhang WB, Zhong WJ, Wang L (2014) A signal-amplification circuit between miR-218 and Wnt\/beta-catenin signal promotes human adipose tissue-derived stem cells osteogenic differentiation. Bone 58:59\u201366. https:\/\/doi.org\/10.1016\/j.bone.2013.09.015","journal-title":"Bone"},{"issue":"1","key":"6523_CR46","doi-asserted-by":"publisher","first-page":"532","DOI":"10.1186\/s13287-020-02026-6","volume":"11","author":"S Melnik","year":"2020","unstructured":"Melnik S, Gabler J, Dreher SI, Hecht N, Hofmann N, Gro\u00dfner T, Richter W (2020) MiR-218 affects hypertrophic differentiation of human mesenchymal stromal cells during chondrogenesis via targeting RUNX2, MEF2C, and COL10A1. Stem Cell Res Ther 11(1):532. https:\/\/doi.org\/10.1186\/s13287-020-02026-6","journal-title":"Stem Cell Res Ther"},{"key":"6523_CR47","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/j.bbrc.2021.05.098","volume":"566","author":"Z Zhang","year":"2021","unstructured":"Zhang Z, Jiang W, Hu M, Gao R, Zhou X (2021) MiR-486-3p promotes osteogenic differentiation of BMSC by targeting CTNNBIP1 and activating the Wnt\/beta-catenin pathway. Biochem Biophys Res Commun 566:59\u201366. https:\/\/doi.org\/10.1016\/j.bbrc.2021.05.098","journal-title":"Biochem Biophys Res Commun"},{"issue":"13","key":"6523_CR48","doi-asserted-by":"publisher","first-page":"17190","DOI":"10.18632\/aging.203169","volume":"13","author":"Y Wei","year":"2021","unstructured":"Wei Y, Ma H, Zhou H, Yin H, Yang J, Song Y, Yang B (2021) miR-424-5p shuttled by bone marrow stem cells-derived exosomes attenuates osteogenesis via regulating WIF-mediated Wnt\/beta-catenin axis. Aging (Albany NY) 13(13):17190\u201317201. https:\/\/doi.org\/10.18632\/aging.203169","journal-title":"Aging (Albany NY)"},{"issue":"1","key":"6523_CR49","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1186\/s13062-021-00302-w","volume":"16","author":"Y Huang","year":"2021","unstructured":"Huang Y, Wan S, Yang M (2021) Circ_0067680 expedites the osteogenic differentiation of human bone marrow-derived mesenchymal stem cells through miR-4429\/CTNNB1\/Wnt\/beta-catenin pathway. Biol Direct 16(1):16. https:\/\/doi.org\/10.1186\/s13062-021-00302-w","journal-title":"Biol Direct"},{"issue":"3","key":"6523_CR50","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1002\/tox.23425","volume":"37","author":"Y Lu","year":"2022","unstructured":"Lu Y, Liu YK, Wan FY, Shi S, Tao R (2022) CircSmg5 stimulates the osteogenic differentiation of bone marrow mesenchymal stem cells by targeting the miR-194-5p\/Fzd6 axis and beta-catenin signaling. Environ Toxicol 37(3):593\u2013602. https:\/\/doi.org\/10.1002\/tox.23425","journal-title":"Environ Toxicol"},{"key":"6523_CR51","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.bone.2016.10.007","volume":"96","author":"J Delgado-Calle","year":"2017","unstructured":"Delgado-Calle J, Sato AY, Bellido T (2017) Role and mechanism of action of sclerostin in bone. Bone 96:29\u201337. https:\/\/doi.org\/10.1016\/j.bone.2016.10.007","journal-title":"Bone"},{"issue":"3","key":"6523_CR52","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1016\/j.cytogfr.2005.02.005","volume":"16","author":"RL van Bezooijen","year":"2005","unstructured":"van Bezooijen RL, ten Dijke P, Papapoulos SE, L\u00f6wik CW (2005) SOST\/sclerostin, an osteocyte-derived negative regulator of bone formation. Cytokine Growth Factor Rev 16(3):319\u2013327. https:\/\/doi.org\/10.1016\/j.cytogfr.2005.02.005","journal-title":"Cytokine Growth Factor Rev"},{"issue":"4","key":"6523_CR53","doi-asserted-by":"publisher","first-page":"828","DOI":"10.1016\/j.bone.2004.05.023","volume":"35","author":"MK Sutherland","year":"2004","unstructured":"Sutherland MK, Geoghegan JC, Yu C, Turcott E, Skonier JE, Winkler DG (2004) Latham J. Sclerostin promotes the apoptosis of human osteoblastic cells: a novel regulation of bone formation. Bone 35(4):828\u2013835. https:\/\/doi.org\/10.1016\/j.bone.2004.05.023","journal-title":"Bone"},{"issue":"8","key":"6523_CR54","doi-asserted-by":"publisher","first-page":"1901","DOI":"10.1002\/jcb.24537","volume":"114","author":"K Ota","year":"2013","unstructured":"Ota K, Quint P, Ruan M, Pederson L, Westendorf JJ, Khosla S, Oursler MJ (2013) Sclerostin is expressed in osteoclasts from aged mice and reduces osteoclast-mediated stimulation of mineralization. J Cell Biochem 114(8):1901\u20131907. https:\/\/doi.org\/10.1002\/jcb.24537","journal-title":"J Cell Biochem"},{"issue":"22","key":"6523_CR55","doi-asserted-by":"publisher","first-page":"19489","DOI":"10.1074\/jbc.M110.190330","volume":"286","author":"O Leupin","year":"2011","unstructured":"Leupin O, Piters E, Halleux C, Hu S, Kramer I, Morvan F, Bouwmeester T, Schirle M, Bueno-Lozano M, Fuentes FJ, Itin PH, Boudin E, de Freitas F, Jennes K, Brannetti B, Charara N, Ebersbach H, Geisse S, Lu CX, Bauer A, Van Hul W, Kneissel M (2011) Bone overgrowth-associated mutations in the LRP4 gene impair sclerostin facilitator function. J Biol Chem 286(22):19489\u201319500. https:\/\/doi.org\/10.1074\/jbc.M110.190330","journal-title":"J Biol Chem"},{"issue":"3","key":"6523_CR56","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1016\/j.jbspin.2004.10.008","volume":"72","author":"R Levasseur","year":"2005","unstructured":"Levasseur R, Lacombe D, de Vernejoul MC (2005) LRP5 mutations in osteoporosis-pseudoglioma syndrome and high-bone-mass disorders. Joint Bone Spine 72(3):207\u2013214. https:\/\/doi.org\/10.1016\/j.jbspin.2004.10.008","journal-title":"Joint Bone Spine"},{"issue":"1","key":"6523_CR57","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1086\/338450","volume":"70","author":"RD Little","year":"2002","unstructured":"Little RD, Carulli JP, Del Mastro RG, Dupuis J, Osborne M, Folz C, Manning SP, Swain PM, Zhao SC, Eustace B, Lappe MM, Spitzer L, Zweier S, Braunschweiger K, Benchekroun Y, Hu X, Adair R, Chee L, FitzGerald MG, Tulig C, Caruso A, Tzellas N, Bawa A, Franklin B, McGuire S, Nogues X, Gong G, Allen KM, Anisowicz A, Morales AJ, Lomedico PT, Recker SM, Van Eerdewegh P, Recker RR, Johnson ML (2002) A mutation in the LDL receptor-related protein 5 gene results in the autosomal dominant high-bone-mass trait. Am J Hum Genet 70(1):11\u201319. https:\/\/doi.org\/10.1086\/338450","journal-title":"Am J Hum Genet"},{"issue":"20","key":"6523_CR58","doi-asserted-by":"publisher","first-page":"1513","DOI":"10.1056\/NEJMoa013444","volume":"346","author":"LM Boyden","year":"2002","unstructured":"Boyden LM, Mao J, Belsky J, Mitzner L, Farhi A, Mitnick MA, Wu D, Insogna K, Lifton RP (2002) High bone density due to a mutation in LDL-receptor-related protein 5. N Engl J Med 346(20):1513\u20131521. https:\/\/doi.org\/10.1056\/NEJMoa013444","journal-title":"N Engl J Med"},{"issue":"3","key":"6523_CR59","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1086\/368277","volume":"72","author":"L Van Wesenbeeck","year":"2003","unstructured":"Van Wesenbeeck L, Cleiren E, Gram J, Beals RK, B\u00e9nichou O, Scopelliti D, Key L, Renton T, Bartels C, Gong Y, Warman ML, De Vernejoul MC, Bollerslev J, Van Hul W (2003) Six novel missense mutations in the LDL receptor-related protein 5 (LRP5) gene in different conditions with an increased bone density. Am J Hum Genet 72(3):763\u2013771. https:\/\/doi.org\/10.1086\/368277","journal-title":"Am J Hum Genet"},{"issue":"6","key":"6523_CR60","doi-asserted-by":"publisher","first-page":"960","DOI":"10.1359\/jbmr.2003.18.6.960","volume":"18","author":"P Babij","year":"2003","unstructured":"Babij P, Zhao W, Small C, Kharode Y, Yaworsky PJ, Bouxsein ML, Reddy PS, Bodine PV, Robinson JA, Bhat B, Marzolf J, Moran RA, Bex F (2003) High bone mass in mice expressing a mutant LRP5 gene. J Bone Miner Res 18(6):960\u2013974. https:\/\/doi.org\/10.1359\/jbmr.2003.18.6.960","journal-title":"J Bone Miner Res"},{"issue":"5","key":"6523_CR61","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1093\/hmg\/10.5.537","volume":"10","author":"W Balemans","year":"2001","unstructured":"Balemans W, Ebeling M, Patel N, Van Hul E, Olson P, Dioszegi M, Lacza C, Wuyts W, Van Den Ende J, Willems P, Paes-Alves AF, Hill S, Bueno M, Ramos FJ, Tacconi P, Dikkers FG, Stratakis C, Lindpaintner K, Vickery B, Foernzler D, Van Hul W (2001) Increased bone density in sclerosteosis is due to the deficiency of a novel secreted protein (SOST). Hum Mol Genet 10(5):537\u2013543. https:\/\/doi.org\/10.1093\/hmg\/10.5.537","journal-title":"Hum Mol Genet"},{"issue":"3","key":"6523_CR62","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1086\/318811","volume":"68","author":"ME Brunkow","year":"2001","unstructured":"Brunkow ME, Gardner JC, Van Ness J, Paeper BW, Kovacevich BR, Proll S, Skonier JE, Zhao L, Sabo PJ, Fu Y, Alisch RS, Gillett L, Colbert T, Tacconi P, Galas D, Hamersma H, Beighton P, Mulligan J (2001) Bone dysplasia sclerosteosis results from loss of the SOST gene product, a novel cystine knot-containing protein. Am J Hum Genet 68(3):577\u2013589. https:\/\/doi.org\/10.1086\/318811","journal-title":"Am J Hum Genet"},{"issue":"6","key":"6523_CR63","doi-asserted-by":"publisher","first-page":"860","DOI":"10.1359\/jbmr.080216","volume":"23","author":"X Li","year":"2008","unstructured":"Li X, Ominsky MS, Niu QT, Sun N, Daugherty B, D\u2019Agostin D, Kurahara C, Gao Y, Cao J, Gong J, Asuncion F, Barrero M, Warmington K, Dwyer D, Stolina M, Morony S, Sarosi I, Kostenuik PJ, Lacey DL, Simonet WS, Ke HZ, Paszty C (2008) Targeted deletion of the sclerostin gene in mice results in increased bone formation and bone strength. J Bone Miner Res 23(6):860\u2013869. https:\/\/doi.org\/10.1359\/jbmr.080216","journal-title":"J Bone Miner Res"},{"issue":"23","key":"6523_CR64","doi-asserted-by":"publisher","first-page":"6267","DOI":"10.1093\/emboj\/cdg599","volume":"22","author":"DG Winkler","year":"2003","unstructured":"Winkler DG, Sutherland MK, Geoghegan JC, Yu C, Hayes T, Skonier JE, Shpektor D, Jonas M, Kovacevich BR, Staehling-Hampton K, Appleby M, Brunkow ME, Latham JA (2003) Osteocyte control of bone formation via sclerostin, a novel BMP antagonist. EMBO J 22(23):6267\u20136276. https:\/\/doi.org\/10.1093\/emboj\/cdg599","journal-title":"EMBO J"},{"issue":"2","key":"6523_CR65","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1016\/j.bone.2009.03.676","volume":"45","author":"Q-Y Huang","year":"2009","unstructured":"Huang Q-Y, Li GHY, Kung AWC (2009) The -9247 T\/C polymorphism in the SOST upstream regulatory region that potentially affects C\/EBPalpha and FOXA1 binding is associated with osteoporosis. Bone 45(2):289\u2013294. https:\/\/doi.org\/10.1016\/j.bone.2009.03.676","journal-title":"Bone"},{"issue":"48","key":"6523_CR66","doi-asserted-by":"publisher","first-page":"E5187","DOI":"10.1073\/pnas.1413828111","volume":"111","author":"MK Chang","year":"2014","unstructured":"Chang MK, Kramer I, Huber T, Kinzel B, Guth-Gundel S, Leupin O, Kneissel M (2014) Disruption of Lrp4 function by genetic deletion or pharmacological blockade increases bone mass and serum sclerostin levels. Proc Natl Acad Sci U S A 111(48):E5187\u2013E5195. https:\/\/doi.org\/10.1073\/pnas.1413828111","journal-title":"Proc Natl Acad Sci U S A"},{"key":"6523_CR67","doi-asserted-by":"publisher","first-page":"D514","DOI":"10.1093\/nar\/gki033","volume":"33","author":"A Hamosh","year":"2005","unstructured":"Hamosh A, Scott AF, Amberger JS, Bocchini CA, McKusick VA (2005) Online Mendelian Inheritance in Man (OMIM), a knowledgebase of human genes and genetic disorders. Nucleic Acids Res 33:D514\u2013D517. https:\/\/doi.org\/10.1093\/nar\/gki033","journal-title":"Nucleic Acids Res"},{"issue":"4","key":"6523_CR68","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1359\/jbmr.081206","volume":"24","author":"X Li","year":"2009","unstructured":"Li X, Ominsky MS, Warmington KS, Morony S, Gong J, Cao J, Gao Y, Shalhoub V, Tipton B, Haldankar R, Chen Q, Winters A, Boone T, Geng Z, Niu QT, Ke HZ, Kostenuik PJ, Simonet WS, Lacey DL, Paszty C (2009) Sclerostin antibody treatment increases bone formation, bone mass, and bone strength in a rat model of postmenopausal osteoporosis. J Bone Miner Res 24(4):578\u2013588. https:\/\/doi.org\/10.1359\/jbmr.081206","journal-title":"J Bone Miner Res"},{"issue":"12","key":"6523_CR69","doi-asserted-by":"publisher","first-page":"2647","DOI":"10.1002\/jbmr.182","volume":"25","author":"X Li","year":"2010","unstructured":"Li X, Warmington KS, Niu QT, Asuncion FJ, Barrero M, Grisanti M, Dwyer D, Stouch B, Thway TM, Stolina M, Ominsky MS, Kostenuik PJ, Simonet WS, Paszty C, Ke HZ (2010) Inhibition of sclerostin by monoclonal antibody increases bone formation, bone mass, and bone strength in aged male rats. J Bone Miner Res 25(12):2647\u20132656. https:\/\/doi.org\/10.1002\/jbmr.182","journal-title":"J Bone Miner Res"},{"issue":"5","key":"6523_CR70","doi-asserted-by":"publisher","first-page":"948","DOI":"10.1002\/jbmr.14","volume":"25","author":"MS Ominsky","year":"2010","unstructured":"Ominsky MS, Vlasseros F, Jolette J, Smith SY, Stouch B, Doellgast G, Gong J, Gao Y, Cao J, Graham K, Tipton B, Cai J, Deshpande R, Zhou L, Hale MD, Lightwood DJ, Henry AJ, Popplewell AG, Moore AR, Robinson MK, Lacey DL, Simonet WS, Paszty C (2010) Two doses of sclerostin antibody in cynomolgus monkeys increases bone formation, bone mineral density, and bone strength. J Bone Miner Res 25(5):948\u2013959. https:\/\/doi.org\/10.1002\/jbmr.14","journal-title":"J Bone Miner Res"},{"issue":"11","key":"6523_CR71","doi-asserted-by":"publisher","first-page":"2412","DOI":"10.1002\/jbmr.135","volume":"25","author":"F Agholme","year":"2010","unstructured":"Agholme F, Li X, Isaksson H, Ke HZ, Aspenberg P (2010) Sclerostin antibody treatment enhances metaphyseal bone healing in rats. J Bone Miner Res 25(11):2412\u20132418. https:\/\/doi.org\/10.1002\/jbmr.135","journal-title":"J Bone Miner Res"},{"issue":"5","key":"6523_CR72","doi-asserted-by":"publisher","first-page":"1012","DOI":"10.1002\/jbmr.307","volume":"26","author":"MS Ominsky","year":"2011","unstructured":"Ominsky MS, Li C, Li X, Tan HL, Lee E, Barrero M, Asuncion FJ, Dwyer D, Han CY, Vlasseros F, Samadfam R, Jolette J, Smith SY, Stolina M, Lacey DL, Simonet WS, Paszty C, Li G, Ke HZ (2011) Inhibition of sclerostin by monoclonal antibody enhances bone healing and improves bone density and strength of nonfractured bones. J Bone Miner Res 26(5):1012\u20131021. https:\/\/doi.org\/10.1002\/jbmr.307","journal-title":"J Bone Miner Res"},{"issue":"4","key":"6523_CR73","doi-asserted-by":"publisher","first-page":"788","DOI":"10.1002\/jbmr.3036","volume":"32","author":"MS Ominsky","year":"2017","unstructured":"Ominsky MS, Boyd SK, Varela A, Jolette J, Felx M, Doyle N, Mellal N, Smith SY, Locher K, Buntich S, Pyrah I, Boyce RW (2017) Romosozumab improves bone mass and strength while maintaining bone quality in ovariectomized cynomolgus monkeys. J Bone Miner Res 32(4):788\u2013801. https:\/\/doi.org\/10.1002\/jbmr.3036","journal-title":"J Bone Miner Res"},{"issue":"1","key":"6523_CR74","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1159\/000173740","volume":"71","author":"M Alharbi","year":"2009","unstructured":"Alharbi M, Pinto G, Finidori G, Souberbielle JC, Guillou F, Gaubicher S, Le Merrer M, Polak M (2009) Pamidronate treatment of children with moderate-to-severe osteogenesis imperfecta: a note of caution. Horm Res 71(1):38\u201344. https:\/\/doi.org\/10.1159\/000173740","journal-title":"Horm Res"},{"issue":"1","key":"6523_CR75","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1002\/jbmr.1717","volume":"28","author":"BP Sinder","year":"2013","unstructured":"Sinder BP, Eddy MM, Ominsky MS, Caird MS, Marini JC, Kozloff KM (2013) Sclerostin antibody improves skeletal parameters in a Brtl\/+ mouse model of osteogenesis imperfecta. J Bone Miner Res 28(1):73\u201380. https:\/\/doi.org\/10.1002\/jbmr.1717","journal-title":"J Bone Miner Res"},{"issue":"8","key":"6523_CR76","doi-asserted-by":"publisher","first-page":"2097","DOI":"10.1007\/s001","volume":"25","author":"BP Sinder","year":"2014","unstructured":"Sinder BP, White LE, Salemi JD, Ominsky MS, Caird MS, Marini JC, Kozloff KM (2014) Adult Brtl\/+ mouse model of osteogenesis imperfecta demonstrates anabolic response to sclerostin antibody treatment with increased bone mass and strength. Osteoporos Int 25(8):2097\u20132107. https:\/\/doi.org\/10.1007\/s001","journal-title":"Osteoporos Int"},{"key":"6523_CR77","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1016\/j.bone.2014.10.012.98-014-2737-y","volume":"71","author":"BP Sinder","year":"2015","unstructured":"Sinder BP, Salemi JD, Ominsky MS, Caird MS, Marini JC, Kozloff KM (2015) Rapidly growing Brtl\/+ mouse model of osteogenesis imperfecta improves bone mass and strength with sclerostin antibody treatment. Bone 71:115\u2013123. https:\/\/doi.org\/10.1016\/j.bone.2014.10.012.98-014-2737-y","journal-title":"Bone"},{"key":"6523_CR78","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1016\/j.bone.2014.06.015","volume":"66","author":"A Roschger","year":"2014","unstructured":"Roschger A, Roschger P, Keplingter P, Klaushofer K, Abdullah S, Kneissel M, Rauch F (2014) Effect of sclerostin antibody treatment in a mouse model of severe osteogenesis imperfecta. Bone 66:182\u2013188. https:\/\/doi.org\/10.1016\/j.bone.2014.06.015","journal-title":"Bone"},{"key":"6523_CR79","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1016\/j.bone.2019.04.011","volume":"124","author":"M Cardinal","year":"2019","unstructured":"Cardinal M, Tys J, Roels T, Lafont S, Ominsky MS, Devogelaer JP, Chappard D, Mabilleau G, Ammann P, Nyssen-Behets C, Manicourt DH (2019) Sclerostin antibody reduces long bone fractures in the oim\/oim model of osteogenesis imperfecta. Bone 124:137\u2013147. https:\/\/doi.org\/10.1016\/j.bone.2019.04.011","journal-title":"Bone"},{"issue":"5","key":"6523_CR80","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1007\/s00223-019-00655-5","volume":"106","author":"M Cardinal","year":"2020","unstructured":"Cardinal M, Dessain A, Roels T, Lafont S, Ominsky MS, Devogelaer JP, Chappard D, Mabilleau G, Ammann P, Nyssen-Behets C, Manicourt DH (2020) Sclerostin-antibody treatment decreases fracture rates in axial skeleton and improves the skeletal phenotype in growing oim\/oim mice. Calcif Tissue Int 106(5):494\u2013508. https:\/\/doi.org\/10.1007\/s00223-019-00655-5","journal-title":"Calcif Tissue Int"},{"key":"6523_CR81","doi-asserted-by":"publisher","first-page":"705505","DOI":"10.3389\/fgene.2021.705505","volume":"12","author":"M Cardinal","year":"2021","unstructured":"Cardinal M, Chretien A, Roels T, Lafont S, Ominsky MS, Devogelaer JP, Manicourt DH, Behets C (2021) Gender-related impact of sclerostin antibody on bone in the osteogenesis imperfecta mouse. Front Genet 12:705505. https:\/\/doi.org\/10.3389\/fgene.2021.705505","journal-title":"Front Genet"},{"issue":"211","key":"6523_CR82","doi-asserted-by":"publisher","first-page":"211ra158","DOI":"10.1126\/scitranslmed.3006627","volume":"5","author":"R Kedlaya","year":"2013","unstructured":"Kedlaya R, Veera S, Horan DJ, Moss RE, Ayturk UM, Jacobsen CM, Bowen ME, Paszty C, Warman ML, Robling AG (2013) Sclerostin inhibition reverses skeletal fragility in an Lrp-deficient mouse model of OPPG syndrome. Sci Transl Med 5(211):211ra158. https:\/\/doi.org\/10.1126\/scitranslmed.3006627","journal-title":"Sci Transl Med"},{"issue":"12","key":"6523_CR83","doi-asserted-by":"publisher","first-page":"4785","DOI":"10.1210\/en.2013-1905","volume":"155","author":"X Li","year":"2014","unstructured":"Li X, Niu QT, Warmington KS, Asuncion FJ, Dwyer D, Grisanti M, Han CY, Stolina M, Eschenberg MJ, Kostenuik PJ, Simonet WS, Ominsky MS, Ke HZ (2014) Progressive increases in bone mass and bone strength in an ovariectomized rat model of osteoporosis after 26 weeks of treatment with a sclerostin antibody. Endocrinology 155(12):4785\u20134797. https:\/\/doi.org\/10.1210\/en.2013-1905","journal-title":"Endocrinology"},{"issue":"7\u20138","key":"6523_CR84","doi-asserted-by":"publisher","first-page":"5679","DOI":"10.1002\/jcp.29500","volume":"235","author":"A Gingery","year":"2020","unstructured":"Gingery A, Subramaniam M, Pitel KS, Li X, Ke HZ, Turner RT, Iwaniec UT, Hawse JR (2020) Sclerostin antibody treatment rescues the osteopenic bone phenotype of TGFbeta inducible early gene-1 knockout female mice. J Cell Physiol 235(7\u20138):5679\u20135688. https:\/\/doi.org\/10.1002\/jcp.29500","journal-title":"J Cell Physiol"},{"issue":"10","key":"6523_CR85","doi-asserted-by":"publisher","first-page":"2297","DOI":"10.1002\/jbmr.2198","volume":"29","author":"CM Jacobsen","year":"2014","unstructured":"Jacobsen CM, Barber LA, Ayturk UM, Roberts HJ, Deal LE, Schwartz MA, Weis M, Eyre D, Zurakowski D, Robling AG, Warman ML (2014) Targeting the LRP5 pathway improves bone properties in a mouse model of osteogenesis imperfecta. J Bone Miner Res 29(10):2297\u20132306. https:\/\/doi.org\/10.1002\/jbmr.2198","journal-title":"J Bone Miner Res"},{"issue":"5","key":"6523_CR86","doi-asserted-by":"publisher","first-page":"1030","DOI":"10.1002\/jbmr.2776","volume":"31","author":"I Grafe","year":"2016","unstructured":"Grafe I, Alexander S, Yang T, Lietman C, Homan EP, Munivez E, Chen Y, Jiang MM, Bertin T, Dawson B, Asuncion F, Ke HZ, Ominsky MS, Lee B (2016) Sclerostin antibody treatment improves the bone phenotype of Crtap(-\/-) mice, a model of recessive osteogenesis imperfecta. J Bone Miner Res 31(5):1030\u20131040. https:\/\/doi.org\/10.1002\/jbmr.2776","journal-title":"J Bone Miner Res"},{"key":"6523_CR87","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1007\/s10354-019-00721-5","volume":"170","author":"K Kerschan-Schindl","year":"2020","unstructured":"Kerschan-Schindl K (2020) Romosozumab: a novel bone anabolic treatment option for osteoporosis? Wien Med Wochenschr 170:124\u2013131. https:\/\/doi.org\/10.1007\/s10354-019-00721-5","journal-title":"Wien Med Wochenschr"},{"issue":"5","key":"6523_CR88","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1177\/1060028020952764","volume":"55","author":"KL Nealy","year":"2021","unstructured":"Nealy KL, Harris KB (2021) Romosozumab: a novel injectable sclerostin inhibitor with anabolic and antiresorptive effects for osteoporosis. Ann Pharmacother 55(5):677\u2013686. https:\/\/doi.org\/10.1177\/1060028020952764","journal-title":"Ann Pharmacother"},{"issue":"9","key":"6523_CR89","doi-asserted-by":"publisher","first-page":"3183","DOI":"10.1210\/jc.2017-02163","volume":"103","author":"EM Lewiecki","year":"2018","unstructured":"Lewiecki EM, Blicharski T, Goemaere S, Lippuner K, Meisner PD, Miller PD, Miyauchi A, Maddox J, Chen L, Horlait S (2018) A phase III randomized placebo-controlled trial to evaluate efficacy and safety of romosozumab in men with osteoporosis. J Clin Endocrinol Metab 103(9):3183\u20133193. https:\/\/doi.org\/10.1210\/jc.2017-02163","journal-title":"J Clin Endocrinol Metab"},{"issue":"15","key":"6523_CR90","doi-asserted-by":"publisher","first-page":"1417","DOI":"10.1056\/NEJMoa1708322","volume":"377","author":"KG Saag","year":"2017","unstructured":"Saag KG, Petersen J, Brandi ML, Karaplis AC, Lorentzon M, Thomas T, Maddox J, Fan M, Meisner PD, Grauer A (2017) Romosozumab or alendronate for fracture prevention in women with osteoporosis. N Engl J Med 377(15):1417\u20131427. https:\/\/doi.org\/10.1056\/NEJMoa1708322","journal-title":"N Engl J Med"},{"issue":"1","key":"6523_CR91","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1007\/s11914-020-00652-w","volume":"19","author":"C Fixen","year":"2021","unstructured":"Fixen C, Tunoa J (2021) Romosozumab: a review of efficacy, safety, and cardiovascular risk. Curr Osteoporos Rep 19(1):15\u201322. https:\/\/doi.org\/10.1007\/s11914-020-00652-w","journal-title":"Curr Osteoporos Rep"},{"issue":"12","key":"6523_CR92","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1161\/hh2401.101070","volume":"89","author":"SA Steitz","year":"2001","unstructured":"Steitz SA, Speer MY, Curinga G, Yang HY, Haynes P, Aebersold R, Schinke T, Karsenty G, Giachelli CM (2001) Smooth muscle cell phenotypic transition associated with calcification: upregulation of Cbfa1 and downregulation of smooth muscle lineage markers. Circ Res 89(12):1147\u20131154. https:\/\/doi.org\/10.1161\/hh2401.101070","journal-title":"Circ Res"},{"issue":"5","key":"6523_CR93","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0019595","volume":"6","author":"D Zhu","year":"2011","unstructured":"Zhu D, Wallace Mackenzie NC, Mill\u00e1n JL, Farquharson C, MacRae VE (2011) The appearance and modulation of osteocyte marker expression during calcification of vascular smooth muscle cells. PLoS ONE 6(5):e19595. https:\/\/doi.org\/10.1371\/journal.pone.0019595","journal-title":"PLoS ONE"},{"issue":"4","key":"6523_CR94","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1002\/jbmr.4503","volume":"37","author":"A De Mar\u00e9","year":"2022","unstructured":"De Mar\u00e9 A, Opdebeeck B, Neven E, D\u2019Haese PC, Verhulst A (2022) Sclerostin protects against vascular calcification development in mice. J Bone Miner Res 37(4):687\u2013699. https:\/\/doi.org\/10.1002\/jbmr.4503","journal-title":"J Bone Miner Res"},{"issue":"4","key":"6523_CR95","doi-asserted-by":"publisher","first-page":"935","DOI":"10.1002\/jbmr.2092","volume":"29","author":"J McColm","year":"2014","unstructured":"McColm J, Hu L, Womack T, Tang CC, Chiang AY (2014) Single- and multiple-dose randomized studies of blosozumab, a monoclonal antibody against sclerostin, in healthy postmenopausal women. J Bone Miner Res 29(4):935\u2013943. https:\/\/doi.org\/10.1002\/jbmr.2092","journal-title":"J Bone Miner Res"},{"issue":"2","key":"6523_CR96","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1002\/jbmr.2351","volume":"30","author":"RR Recker","year":"2015","unstructured":"Recker RR, Benson CT, Matsumoto T, Bolognese MA, Robins DA, Alam J, Chiang AY, Hu L, Krege JH, Sowa H, Mitlak BH, Myers SL (2015) A randomized, double-blind phase 2 clinical trial of blosozumab, a sclerostin antibody, in postmenopausal women with low bone mineral density. J Bone Miner Res 30(2):216\u2013224. https:\/\/doi.org\/10.1002\/jbmr.2351","journal-title":"J Bone Miner Res"},{"key":"6523_CR97","volume":"9","author":"NM Appelman-Dijkstra","year":"2022","unstructured":"Appelman-Dijkstra NM, Oei HLDW, Vlug AG (2022) Winter EM (2022) Best Pract Res Clin Endocrinol Metab. In press Corrected proof available online 9:101623","journal-title":"In press Corrected proof available online"},{"issue":"7","key":"6523_CR98","doi-asserted-by":"publisher","first-page":"1496","DOI":"10.1002\/jbmr.3143","volume":"32","author":"FH Glorieux","year":"2017","unstructured":"Glorieux FH, Devogelaer JP, Durigova M, Goemaere S, Hemsley S, Jakob F, Junker U, Ruckle J, Seefried L, Winkle PJ (2017) BPS804 anti-sclerostin antibody in adults with moderate osteogenesis imperfecta: results of a randomized phase 2a trial. J Bone Miner Res 32(7):1496\u20131504. https:\/\/doi.org\/10.1002\/jbmr.3143","journal-title":"J Bone Miner Res"},{"issue":"6","key":"6523_CR99","doi-asserted-by":"publisher","first-page":"2148","DOI":"10.1172\/JCI83731","volume":"127","author":"L Seefried","year":"2017","unstructured":"Seefried L, Baumann J, Hemsley S, Hofmann C, Kunstmann E, Kiese B, Huang Y, Chivers S, Valentin MA, Borah B, Roubenoff R, Junker U, Jakob F (2017) Efficacy of anti-sclerostin monoclonal antibody BPS804 in adult patients with hypophosphatasia. J Clin Invest 127(6):2148\u20132158. https:\/\/doi.org\/10.1172\/JCI83731","journal-title":"J Clin Invest"}],"container-title":["Osteoporosis International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00198-022-06523-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00198-022-06523-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00198-022-06523-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,23]],"date-time":"2023-01-23T12:43:38Z","timestamp":1674477818000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00198-022-06523-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8,18]]},"references-count":99,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2023,2]]}},"alternative-id":["6523"],"URL":"https:\/\/doi.org\/10.1007\/s00198-022-06523-7","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.742287570.793595581","asserted-by":"object"}]},"ISSN":["0937-941X","1433-2965"],"issn-type":[{"value":"0937-941X","type":"print"},{"value":"1433-2965","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,8,18]]},"assertion":[{"value":"2 March 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 August 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 August 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"None.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}}]}}